Trial Profile
A Phase II Study Using SGN-15 (cBR96 - Doxorubicin Immunoconjugate) in Combination With Taxotere for the Treatment of Advanced Stage or Recurrent Non-Small Cell Lung Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Sep 2021
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; SGN-15 (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Seagen
- 03 Sep 2005 New trial record.